CALA - Calithera Biosciences, Inc.
| Previous Close | 4.5700 |
| Open | 4.5900 |
| Bid | 4.30 x 1100 |
| Ask | 5.06 x 900 |
| Day's Range | 4.4400 - 4.6500 |
| 52 Week Range | 3.5500 - 9.3500 |
| Volume | 127,615 |
| Avg. Volume | 295,188 |
| Market Cap | 170.041M |
| Beta (3Y Monthly) | 1.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.28 |
| Earnings Date | Nov 7, 2017 - Nov 13, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.25 |
- Simply Wall St.•3 days ago
What Did Calithera Biosciences, Inc.’s (NASDAQ:CALA) CEO Take Home Last Year?
In 2010 Susan Molineaux was appointed CEO of Calithera Biosciences, Inc. (NASDAQ:CALA). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that, Read More...
- GlobeNewswire•15 days ago
Calithera Biosciences Provides Corporate Updates and Announces Key Executive Promotions to Drive Continued Growth of the Company’s Pipeline
Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced several executive promotions. "I am pleased to announce today's promotions which highlight the talent, skill set and extensive achievements of our executive team," said Susan Molineaux, PhD, President and Chief Executive Officer of Calithera. "It is critical that we have the right leadership in place to reach key clinical milestones as we drive CB-839 towards commercialization with two randomized trials of the glutaminase inhibitor CB-839 for the treatment of patients with advanced renal cell carcinoma.
- GlobeNewswire•2 months ago
Calithera Biosciences to Participate in the 2018 Citi Global Healthcare Conference
Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced its participation at the 2018 Citi Global Healthcare Conference. Calithera will host meetings with investors at the conference in New York on Thursday, December 6, 2018. Calithera is a clinical-stage biopharmaceutical company focused on fighting cancer by discovering, developing, and commercializing novel small molecule drugs that target tumor and immune cell metabolism. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.
- Simply Wall St.•2 months ago
Intrinsic Calculation For Calithera Biosciences Inc (NASDAQ:CALA) Shows Investors Are Overpaying
Does the November share price for Calithera Biosciences Inc (NASDAQ:CALA) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value by taking the expected future cash flows and Read More...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of CALA earnings conference call or presentation 7-Nov-18 10:00pm GMT
Q3 2018 Calithera Biosciences Inc Earnings Call
- Zacks•2 months ago
Calithera (CALA) Reports Q3 Loss, Lags Revenue Estimates
Calithera (CALA) delivered earnings and revenue surprises of -26.83% and -100.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Calithera: 3Q Earnings Snapshot
On a per-share basis, the South San Francisco, California-based company said it had a loss of 52 cents. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
- GlobeNewswire•2 months ago
Calithera Biosciences Reports Third Quarter 2018 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel.
- GlobeNewswire•3 months ago
Calithera Biosciences to Report Third Quarter 2018 Financial Results on Wednesday, November 7, 2018
Calithera Biosciences, Inc. (CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that the Company’s third quarter 2018 financial results will be released on Wednesday, November 7, 2018. Company management will host a conference call on Wednesday, November 7, 2018 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights. The press release and live audio webcast can be accessed via the Investor section of the Company’s website at www.calithera.com.
- Simply Wall St.•4 months ago
What Investors Should Know About Calithera Biosciences Inc’s (NASDAQ:CALA) Financial Strength
Calithera Biosciences Inc (NASDAQ:CALA), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is CALA Read More...
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of CALA earnings conference call or presentation 7-Aug-18 9:00pm GMT
Q2 2018 Calithera Biosciences Inc Earnings Call
- Zacks•5 months ago
Calithera (CALA) Reports Q2 Loss, Tops Revenue Estimates
Calithera (CALA) delivered earnings and revenue surprises of 72.73% and 230.40%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•5 months ago
Calithera: 2Q Earnings Snapshot
The South San Francisco, California-based company said it had a loss of 9 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- ACCESSWIRE•5 months ago
Calithera Biosciences, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Calithera Biosciences, Inc. (NASDAQ: CALA ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 5:00 PM Eastern ...
- ACCESSWIRE•7 months ago
Complimentary Technical Snapshots on Celgene and Three More Biotech Stocks
Four stocks have been lined up for today's assessment, and they are: Calithera Biosciences Inc. (CALA), Cara Therapeutics Inc. (CARA), Celgene Corp. (CELG), and Celldex Therapeutics Inc. (CLDX). Shares in South San Francisco, California headquartered Calithera Biosciences Inc. jumped 5.53%, ending Wednesday's trading session at $5.25. The stock recorded a trading volume of 552,298 shares, which was higher than its three months average volume of 426,620 shares.
